Sun Pharmaceutical Industries Ltd. - Research Center
524715 SUNPHARMA Group (A) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 24 | Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | |
|---|---|---|---|---|---|
| Sales | 20,275.17 | 20,812.14 | 15,585.98 | 12,803.21 | 12,531.93 |
| Operating profit | 5,587.61 | 6,472.86 | 2,907.52 | 2,936.00 | 2,711.65 |
| Interest | 784.08 | 472.18 | 388.10 | 256.98 | 408.01 |
| Gross profit | 5,269.29 | 6,279.71 | 3,477.34 | 2,829.24 | 3,814.56 |
| EPS (Rs) | 11.91 | 7.05 | -0.42 | 8.92 | 13.38 |
Annual
results in details
| Mar ' 24 | Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | |
|---|---|---|---|---|---|
| Other income | 465.76 | 279.03 | 957.92 | 150.22 | 1,510.92 |
| Stock adjustment | 180.32 | -237.93 | -183.18 | -214.84 | 138.60 |
| Raw material | 4,429.38 | 5,165.63 | 4,584.97 | 3,809.11 | 3,201.71 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 2,373.95 | 2,156.95 | 2,000.78 | 1,798.45 | 1,702.77 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 7,703.91 | 7,254.63 | 6,275.89 | 4,474.49 | 4,777.20 |
| Provisions made | - | - | - | - | - |
| Depreciation | 1,600.62 | 1,600.87 | 1,349.95 | 586.81 | 561.56 |
| Taxation | 591.47 | 50.33 | 406.85 | 13.17 | 41.86 |
| Net profit / loss | 2,858.18 | 1,690.72 | -99.99 | 2,139.70 | 3,211.14 |
| Extra ordinary item | -219.02 | -2,937.79 | -1,820.53 | -89.56 | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 239.93 | 239.93 | 239.93 | 239.93 | 239.93 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 27.56 | 31.10 | 18.65 | 22.93 | 21.64 |
| GPM (%) | 25.41 | 29.77 | 21.02 | 21.84 | 27.16 |
| NPM (%) | 13.78 | 8.02 | -0.60 | 16.52 | 22.87 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis